Vitality Watch

Dossier clinicaltrials other 09-jul-2026
Doesn't fit the ladder

In Vivo Noradrenergic System and Aging

Key claim: A proposed human PET/MRI study will map age- and Parkinson’s-related changes in the noradrenergic system with the alpha2C-AR radiotracer [11C]ORM-13070 and test whether those changes parallel cognitive, motor, and olfactory performance.

Abstract

The main goal of this research proposal is to provide, for the first time in humans, a wider understanding of the role of the noradrenergic system both in health and illness (here Parkinson’s disease) through the use of a newly developed radiotracer visualizing alpha2C-ARs ([11C]ORM-13070) combined with a cutting-edge technology, the hybrid PET/MRI scanner. The secondary aim will be to determine whether the expected age- and PD-related changes in the noradrenergic system are paralleled by changes in neuropsychological performances (i.e. cognitive, motor and/or olfactory abilities).

Why this matters

A proposed human PET/MRI study will map age- and Parkinson’s-related changes in the noradrenergic system with the alpha2C-AR radiotracer [11C]ORM-13070 and test whether those changes parallel cognitive, motor, and olfactory performance.

Source

Link

Briefing card

In Vivo Noradrenergic System and Aging
Stage: other · clinicaltrials · 09-jul-2026

A proposed human PET/MRI study will map age- and Parkinson's-related changes in the noradrenergic system with the alpha2C-AR radiotracer [11C]ORM-13070 and test whether those changes parallel cognitive, motor, and olfactory performance.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07569120

build build 880 · 2bcef25 · 2026-11-18